Related Experiment Video

Updated: Jul 20, 2026

Analysis of Retinoic Acid-induced Neural Differentiation of Mouse Embryonic Stem Cells in Two and Three-dimensional Embryoid Bodies
09:04

Analysis of Retinoic Acid-induced Neural Differentiation of Mouse Embryonic Stem Cells in Two and Three-dimensional Embryoid Bodies

Published on: April 22, 2017

Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic

K J Soprano1, E Purev, S Vuocolo

  • 1Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA 19140, USA. sopranok@temple.edu

Oncogene
|August 29, 2006
PubMed

Insights

All-trans-retinoic acid (ATRA) increases Rb2/p130 protein stability in ovarian cancer cells by preventing its degradation. This mechanism involves PP2A dephosphorylation, leading to nuclear translocation and cell cycle arrest, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Ovarian cancer remains a leading cause of gynecological cancer mortality, necessitating novel therapeutic strategies.
  • All-trans-retinoic acid (ATRA) has demonstrated anti-proliferative effects on ovarian carcinoma cells.
  • Rb2/p130, a tumor suppressor protein, is upregulated by ATRA, but the underlying mechanism requires elucidation.

Purpose of the Study:

  • To investigate the molecular mechanism by which ATRA enhances Rb2/p130 protein levels in ovarian cancer.
  • To determine the role of protein stability and degradation pathways in ATRA-mediated Rb2/p130 regulation.
  • To explore the implications of Rb2/p130 nuclear translocation for ovarian cancer cell proliferation.

Main Methods:

  • Treatment of ovarian carcinoma cells with All-trans-retinoic acid (ATRA).
  • Analysis of Rb2/p130 protein and mRNA levels, protein stability, ubiquitination, and proteasomal degradation.
  • Investigation of the interaction between Rb2/p130, protein phosphatase 2A (PP2A), and nuclear transport machinery (importins).

Main Results:

  • ATRA treatment significantly increased Rb2/p130 protein levels without altering mRNA levels, indicating enhanced protein stability.
  • PP2A binds to and dephosphorylates Rb2/p130 at its Nuclear Localization Signal (NLS), reducing its ubiquitination and proteasomal degradation.
  • Dephosphorylated Rb2/p130 interacts with importin alpha and importin beta, facilitating its nuclear translocation and subsequent G1 cell cycle arrest.

Conclusions:

  • ATRA enhances ovarian cancer cell suppression by stabilizing Rb2/p130 protein through PP2A-mediated dephosphorylation and nuclear import.
  • This pathway represents a novel mechanism for targeting ovarian cancer proliferation.
  • Targeting the ATRA-PP2A-Rb2/p130 axis may offer a promising therapeutic avenue for ovarian cancer treatment.

More Related Videos

Inducible and Reversible Dominant-negative (DN) Protein Inhibition08:35

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Published on: January 7, 2019

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...